LongBio Pharma closes IPO offering
LongBio Pharma closed its Hong Kong IPO on June 2 with a 4,470-fold oversubscription, setting a recent market record. The clinical-stage company, which develops allergy and autoimmune disease treatments, plans to use the proceeds to advance its LP-003 and LP-005 drug pipelines.